China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2026-06-19

Summary

This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.

• Phase: PHASE3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: belantamab mafodotin; Bortezomib; daratumumab; Dexamethasone